Vasorum, Ltd. appears in FDA device records as the applicant behind one approved premarket approval application and its supplements. The supplied collection holds two linked PMA records, both with an approval decision, and both tied to P150006 and the Celt ACD Vascular Closure Device. The original application was received on February 3, 2015 and approved on July 20, 2016, with a Federal Register notice date of July 25, 2016. The later record is a supplement, S009, received October 2, 2026 and approved October 30, 2026. These counts describe the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. [1][2][6]

The documented product and its approved indication

The Celt ACD Vascular Closure Device is recorded under generic name Device, hemostasis, vascular, device name Device, Hemostasis, Vascular, and product code MGB, with device class 3 and the Cardiovascular advisory committee. The approval order for P150006 states the indication as percutaneous closure of common femoral artery puncture sites while reducing time-to-hemostasis in patients who have undergone diagnostic or interventional intra-arterial catheterization procedures where either 5F or 6F introducer sheaths have been used. The FDA summary of safety and effectiveness data lists the same trade name and procode and names Vasorum, Ltd at Trinitas House, 2012 Orchard Avenue, Citywest Business Campus, Dublin 24, Ireland, as the applicant. That address is a filing address, not a verified headquarters. [2][6]

Filing history in the linked FDA records

The original P150006 approval carries docket number 16m-2185 and an expedited review flag of N. The S009 supplement is classified as Special (Immediate Track) with supplement reason Labeling Change - Indications/instructions/shelf life/tradename, and its approval order describes changes to the Instructions for Use labeling for a limited number of CELT ACD PLUS 5F device lots. The PMA database page for P150006 notes that the device has supplements and that the device description, function or indication may have changed, and it lists S001, S004, S006 and S007 alongside the labeling link. Those supplements appear only as links in the public information; their contents and decisions are not documented here. [1][2][4]

Labeling and device characteristics

The instructions for use published by Vasorum describe the Celt ACD as MR Conditional, supplied sterile and non-pyrogenic in unopened undamaged packaging, sterilized by ebeam irradiation and intended for single use only, with no latex in the device or primary packaging. The same labeling states that federal law restricts the device to sale by or on the order of a physician or allied healthcare professionals authorized by or under the direction of such a physician who is trained in diagnostic and/or interventional catheterization procedures, and that operators must review the instructions before use. A separate FDA-posted instructions for use version reports non-clinical testing showing the device is MR Conditional, with an image artifact extending approximately 10 mm from the device when imaged using a gradient echo pulse sequence and a 3-Tesla MR system. [7][8]

What the record does and does not establish

The public information documents one approved PMA and one approved supplement for a single device family, plus labeling documents. It does not establish a parent company, brand ownership, customer base, commercial availability, certifications or clinical outcome results, and none should be inferred from the filing record. The two linked records and their approval decisions are a snapshot of the supplied filings at the stated retrieval date. The PMA database page carries a last-updated date of September 7, 2026, which is a page maintenance date rather than a regulatory decision. [1][2][4]